REGULATORY
Comprehensive Strategy Proposal for “Japan NIH” Calls for Study on Legislation to Prevent Clinical Research Fraud by Autumn
The government’s Expert Committee on R&D in the Field of Healthcare (chairman: Ryozo Nagai, President, Jichi Medical University) compiled a proposal for a “comprehensive strategy” that sets forth mid-term and long-term targets for publicly funded clinical research. To deal with…
To read the full story
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Health Minister Signals Early March Approval for iPSC Products
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





